CSL (ASX:CSL) - CEO & Managing Director, Paul Perreault
CEO & Managing Director, Paul Perreault
Source: CSL Behring
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Biotech giant CSL (CSL) has closed its global commercialisation and licence agreement with uniQure for AMT-061
  • Mid last year, CSL agreed to acquire the exclusive global licence rights to commercialise AMT-061 from uniQure for $656 million
  • AMT-061 is uniQure’s novel gene therapy for the treatment of haemophilia B, a blood clotting disorder
  • One dose of AMT-061 has shown to increase Factor IX plasma levels which is a blood clotting protein lacking in people with haemophilia B
  • CSL has ended the day a slight 0.28 per cent in the red with shares trading at $276.89

Biotech giant CSL (CSL) has closed its global commercialisation and licence agreement with uniQure for AMT-061.

Mid last year, CSL agreed to acquire the exclusive global licence rights to commercialise AMT-061 from uniQure for $656 million.

AMT-061, or etranacogene dezaparvovec, is uniQure’s novel gene therapy for the treatment of haemophilia B (blood clotting).

It contains an AAV5 viral vector which has shown to be safe and well-tolerated in many clinical trials. AAV5 moderates gene transfer in an independent manner.

One dose of AMT-061 has shown to increase Factor IX plasma levels which is a naturally produced protein that forms blood clots.

Unfortunately, this protein is highly lacking in haemophilia B patients.

AMT-061 is currently undergoing phase three clinical trials.

“This agreement enables us to take forward a gene therapy, that, if approved, has the potential to transform the lives of haemophilia B patients,” CEO and Managing Director Paul Perreault said.

“Etranacogene dezaparvovec has the potential to be the first-ever gene therapy approved for haemophilia B and help CSL deliver on our ongoing commitment to improving the lives of those living with haemophilia B,” he added.

CSL has ended the day a slight 0.28 per cent in the red with shares trading at $276.89 in a $126.3 billion market cap.

CSL by the numbers
More From The Market Herald
Fortescue Metals Group (ASX:FMG) - Departing CEO, Elizabeth Gaines

" Fortescue Metals (ASX:FMG) records highest number of half-year shipments

Fortescue Metals (ASX:FMG) records its highest number of shipments for a half year at 93.1 million…
Zip CO (ASX:Z1P) - CEO, Larry Diamond

" Zip Co (ASX:Z1P) confirms potential acquisition of Sezzle (ASX:SZL)

Buy now, pay later company Zip Co (ASX:Z1P) confirms it is looking to buy Sezzle (SZL),…

" Fortescue (ASX:FMG) to buy Williams Advanced Engineering for $310m

Fortescue Metals Group (ASX:FMG) plans to acquire technology and engineering services firm Williams Advanced Engineering (WAE)…

" Northern Star Resources (ASX:NST) spikes on December quarter gold sales

Shares in gold mining big-cap Northern Star Resources (ASX:NST) have risen in early action following the…